Cargando…
The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting
BACKGROUND: Clinical outcomes of novel coronavirus 2019 disease (COVID‐19) in onco‐hematological patients are unknown. When compared to non‐immunocompromised patients, onco‐hematological patients seem to have higher mortality rates. AIMS: We describe the characteristics and outcomes of a consecutive...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994963/ https://www.ncbi.nlm.nih.gov/pubmed/33656801 http://dx.doi.org/10.1002/cnr2.1358 |
_version_ | 1783669865516630016 |
---|---|
author | Condom, Maria Mussetti, Alberto Maluquer, Clara Parody, Rocío González‐Barca, Eva Arnan, Montserrat Albasanz‐Puig, Adaia Pomares, Helena Salas, Maria Queralt Carro, Itziar Peña, Marta Clapes, Victòria Baca Cano, Cristina Oliveira Ramos, Ana Carla Sanz‐Linares, Gabriela Moreno‐González, Gabriel Mercadal, Santiago Boqué, Concepcion Gudiol, Carlota Domingo‐Domènech, Eva Sureda, Anna |
author_facet | Condom, Maria Mussetti, Alberto Maluquer, Clara Parody, Rocío González‐Barca, Eva Arnan, Montserrat Albasanz‐Puig, Adaia Pomares, Helena Salas, Maria Queralt Carro, Itziar Peña, Marta Clapes, Victòria Baca Cano, Cristina Oliveira Ramos, Ana Carla Sanz‐Linares, Gabriela Moreno‐González, Gabriel Mercadal, Santiago Boqué, Concepcion Gudiol, Carlota Domingo‐Domènech, Eva Sureda, Anna |
author_sort | Condom, Maria |
collection | PubMed |
description | BACKGROUND: Clinical outcomes of novel coronavirus 2019 disease (COVID‐19) in onco‐hematological patients are unknown. When compared to non‐immunocompromised patients, onco‐hematological patients seem to have higher mortality rates. AIMS: We describe the characteristics and outcomes of a consecutive cohort of 24 onco‐hematological patients with COVID‐19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. METHODS AND RESULTS: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID‐19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22‐82) years. Median follow‐up in survivors was 14 (9‐28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1‐10) and 10 (3‐18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D‐dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID‐19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID‐19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (−55%) and chemotherapy sessions (−19%). A significant increase in phone visits was reported (+581%). CONCLUSION: COVID‐19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting. |
format | Online Article Text |
id | pubmed-7994963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79949632021-03-26 The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting Condom, Maria Mussetti, Alberto Maluquer, Clara Parody, Rocío González‐Barca, Eva Arnan, Montserrat Albasanz‐Puig, Adaia Pomares, Helena Salas, Maria Queralt Carro, Itziar Peña, Marta Clapes, Victòria Baca Cano, Cristina Oliveira Ramos, Ana Carla Sanz‐Linares, Gabriela Moreno‐González, Gabriel Mercadal, Santiago Boqué, Concepcion Gudiol, Carlota Domingo‐Domènech, Eva Sureda, Anna Cancer Rep (Hoboken) Original Articles BACKGROUND: Clinical outcomes of novel coronavirus 2019 disease (COVID‐19) in onco‐hematological patients are unknown. When compared to non‐immunocompromised patients, onco‐hematological patients seem to have higher mortality rates. AIMS: We describe the characteristics and outcomes of a consecutive cohort of 24 onco‐hematological patients with COVID‐19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. METHODS AND RESULTS: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID‐19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22‐82) years. Median follow‐up in survivors was 14 (9‐28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1‐10) and 10 (3‐18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D‐dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID‐19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID‐19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (−55%) and chemotherapy sessions (−19%). A significant increase in phone visits was reported (+581%). CONCLUSION: COVID‐19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC7994963/ /pubmed/33656801 http://dx.doi.org/10.1002/cnr2.1358 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Condom, Maria Mussetti, Alberto Maluquer, Clara Parody, Rocío González‐Barca, Eva Arnan, Montserrat Albasanz‐Puig, Adaia Pomares, Helena Salas, Maria Queralt Carro, Itziar Peña, Marta Clapes, Victòria Baca Cano, Cristina Oliveira Ramos, Ana Carla Sanz‐Linares, Gabriela Moreno‐González, Gabriel Mercadal, Santiago Boqué, Concepcion Gudiol, Carlota Domingo‐Domènech, Eva Sureda, Anna The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title_full | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title_fullStr | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title_full_unstemmed | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title_short | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting |
title_sort | direct and indirect effects of covid‐19 pandemic in a real‐life hematological setting |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994963/ https://www.ncbi.nlm.nih.gov/pubmed/33656801 http://dx.doi.org/10.1002/cnr2.1358 |
work_keys_str_mv | AT condommaria thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT mussettialberto thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT maluquerclara thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT parodyrocio thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT gonzalezbarcaeva thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT arnanmontserrat thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT albasanzpuigadaia thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT pomareshelena thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT salasmariaqueralt thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT carroitziar thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT penamarta thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT clapesvictoria thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT bacacanocristina thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT oliveiraramosanacarla thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT sanzlinaresgabriela thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT morenogonzalezgabriel thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT mercadalsantiago thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT boqueconcepcion thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT gudiolcarlota thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT domingodomenecheva thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT suredaanna thedirectandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT condommaria directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT mussettialberto directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT maluquerclara directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT parodyrocio directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT gonzalezbarcaeva directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT arnanmontserrat directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT albasanzpuigadaia directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT pomareshelena directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT salasmariaqueralt directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT carroitziar directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT penamarta directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT clapesvictoria directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT bacacanocristina directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT oliveiraramosanacarla directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT sanzlinaresgabriela directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT morenogonzalezgabriel directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT mercadalsantiago directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT boqueconcepcion directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT gudiolcarlota directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT domingodomenecheva directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting AT suredaanna directandindirecteffectsofcovid19pandemicinareallifehematologicalsetting |